Conclusion, Investment Implications, Strategy

We are exiting our May 28th short idea in Biogen Inc. (BIIB) this morning for a 7%% gain.

Analysis and Rationale

In our May 28th report, entitled Biogen (BIIB) Breaking Down From Indecision, we said:

Biogen Inc. (BIIB) recently broke down from more than 3 months of sideways investor indecision, targeting an additional 31% decline to $209.50 per share that will remain valid below the $316.85 area.  This is an Asbury Momentum idea.

Although our $209.50 downside target still remains intact, BIIB’s recent rebound from underlying support at 262,25 (green highlights) with less than two weeks until Q2 earnings are reported, we are making a money management decision to take a small profit on our short idea.

BIIB daily since August 2019